10 July 2026 : Clinical Research
Effect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects
Satoru Takahashi ABCDE 1, Mihoko Yamade ABCDF 1*, Takahisa Furuta A 2, Tomohiro Higuchi AB 3, Mikihiro Shimizu CD 4, Keisuke Inagaki B 1, Kiichi Sugiura B 1, Tomoharu Matsuura B 5, Natsuki Ishida
B 1, Takanori Yamada B 6, Moriya Iwaizumi F 5, Yasushi Hamaya B 1, Ken Sugimoto F 1, Satoshi Osawa DF 6,7
DOI: 10.12659/MSM.953332
Med Sci Monit 2026; 32:e953332
Table 4 Comparison of 13C-aminopyrine breath test parameters between control and vonoprazan conditions.
| Control (Mean ± SD) | Vonoprazan (Mean ± SD) | GMR (VPZ/Control) | 90% CI | |
|---|---|---|---|---|
| Maximum value of DOB (%dose/h) | 6.46 ± 2.15 | 6.81 ± 2.16 | 1.05 | 0.93–1.18 |
| AUC of DOB (%dose/h) | 14.57 ± 4.26 | 15.90 ± 3.86 | 1.09 | 0.97–1.23 |
| AUC of DOB (%dose/h) | 4.54 ± 1.81 | 4.89 ± 1.41 | 1.08 | 0.91–1.29 |
| AUC of DOB (%dose/h) | 5.35 ± 1.50 | 5.87 ± 1.64 | 1.10 | 0.96–1.26 |
| AUC of DOB (%dose/h) | 4.68 ± 1.28 | 5.14 ± 1.13 | 1.10 | 0.96–1.27 |
| Note: GMR and 90% CI were calculated based on log-transformed data and then back-transformed. GMR > 1 indicates higher value with VPZ. | ||||